Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    GeorgeBest
    wrote on sidst redigeret af
    #785

    Thanks E L & Bulder

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #786

      good luck Helge, looking forward to the summaries tomorrow morning 😉

      1 Reply Last reply
      0
      • DarvinD Offline
        DarvinD Offline
        Darvin
        wrote on sidst redigeret af
        #787

        Rigth EL 17.10 65% increase compared to april 2020 and 46,5% increase compared to først 4 months 2020. Excellent

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #788

          E L I play football tonight with the young people in the club. Must therefore, as usual, go to bed early and get up late tomorrow. 😄

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #789

            a much better way to spend your time lol, enjoy!

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #790

              Well, glofi har 3 pts ud af 52 med CRS grade 3. Epco har ingen over grade 2. Glofi: CRS was mostly(!) manageable.

              1 Reply Last reply
              0
              • P Offline
                P Offline
                peter12
                wrote on sidst redigeret af
                #791

                Media release https://ir.genmab.com/news-releases/news-release-details/genmab-announces-abstracts-evaluating-products-pipeline

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #792

                  Responser synes jeg er svært at udlede, men epco nævner 55% CR og glofi nævner 57,1% CMR i dlbcl. Altså næsten det samme. Med alle forbehold.

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #793

                    Genmab vil præsentere data til kommende konferencer - GENT
                    https://www.proinvestor.com/investornyt/675234/genmab-vil-praesentere-data-til-kommende-konferencer-gent

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #794

                      God morgen. 🙂

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #795

                        Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be
                        Presented at American Society of Clinical Oncology : https://www.proinvestor.com/investornyt/675232/genmab-announces-abstracts-evaluating-products-in-pipeline-portfolio-to-be-presented-at-american-society-of-clinical-oncology

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #796

                          Torsdagens danske avisuddrag med Bitcoin, Salling Group og Rockwool: https://www.proinvestor.com/investornyt/675239/torsdagens-danske-avisuddrag-med-bitcoin-salling-group-og-rockwool

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #797

                            Er svagheden i biotekaktier forbigående?
                            Bryder Novo Nordisk ud af sit kursinterval? Er inflationsfaren reel – eller er det et buzzword? Samt verden ifølge elonmusk
                            & tsla. Lyt med i afsnit 66 af Investeringspodcasten med PerNordnet
                            ogHelgeLarsen. https://www.nordnet.dk/blog/afsnit-66-af-investeringspodcasten-om-biotekaktier-og-verden-ifoelge-elon-musk/
                            .

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #798

                              Bemærkningen “mostly manageable” er da interessant, som også bulder fremhæver 23:35

                              1 Reply Last reply
                              0
                              • JørgenVarnæsJ Offline
                                JørgenVarnæsJ Offline
                                JørgenVarnæs
                                wrote on sidst redigeret af
                                #799

                                Bulder 13.56 tusind tak for info

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #800

                                  ASCO : Updated phase 1 results of teclistamab - https://meetinglibrary.asco.org/record/195433/abstract

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #801

                                    ASCO : Updated results of a phase 1, first-in-human study of talquetamab - https://meetinglibrary.asco.org/record/195432/abstract

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #802

                                      I didn't realise JNJ are also trying Amivantamab subcutaneous WITHOUT hyaluronidase , so just SC administration of a low concentration (50 mg/mL) formulation of amivantamab alone. Let's hope that works well enough. https://meetinglibrary.asco.org/record/201164/abstract

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #803

                                        any thoughts on Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed? https://meetinglibrary.asco.org/record/196820/abstract
                                        not sure if this is the same sub-group as previously presented?

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #804

                                          Bemærker lige at teclis heller ikke har CRS over grade 2. 30% CR som monoterapi er stærkt. Vi er i 6. linje i gns.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger